trial · primary record
baricitinib
Hyper IgE Syndrome From STAT3 Mutation
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2030-10-01 |
| Primary endpoint | Incidence of SAEs, AEs requiring study drug discontinuation. |
| Registry ID | NCT07262983 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:21.534Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07262983
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.